Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.56 |
| ▸ | LAP3 | P28838 | 7/20 | 0.55 |
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.55 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10772763 | 1.00 | SLC15A1 (0.56) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL4619659 | 1.00 | SLC15A1 (0.56) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL289159 | 1.00 | SLC15A1 (0.56) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL9515701 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL6348571 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL21854197 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL540968 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL10775336 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL7698421 | 0.86 | ALPI (0.62) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL2029167 | 0.86 | ALPI (0.62) | SLC15A1LAP3ANPEPRNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846820-B2 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-6649634-B2 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| US-6380220-B1 | THERAPY OF NEURODEGENERATIVE DISEASES AND NEURONAL INJURIES WHICH ARE CASUED BY ISCHEMIA, TRAUMA OR MASSIVE HEMORRHAGES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | disclosed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | disclosed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | disclosed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| US-5952328-A | MAY BE USED TO ALLEVIATE, MEDIATE, REDUCE AND/OR PREVENT DISORDERS WHICH ARE ASSOCIATED WITH ABNORMAL AND/OR ABERRANT ACTIVITY OF CYSTEINE PROTEASES AND/OR SERINE PROTEASES | CEPHALON, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-4668769-A | Oxa- and azahomocyclostatine polypeptides | PFIZER INC. | 1987-05-26 | — | — | US | disclosed |
| EP-0211580-A2 | Renin inhibiting polypeptides and intermediates therefor | PFIZER INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| US-4599198-A | Intermediates in polypeptide synthesis | PFIZER INC. (US) | 1986-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | SLC15A1 1786/4885LAP3 1486/4885ANPEP 941/4885 |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | SLC15A1 1885/4885LAP3 1545/4885ANPEP 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.